250 records found.
Aug 16, 2019
Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15
Aug 12, 2019
Medicines targeting multiple sclerosis and lymphoma are among new specialty drugs available through AllianceRx Walgreens Prime
Jul 23, 2019
Actinium Achieves Fifty Percent Enrollment in the Pivotal Phase 3 SIERRA Trial for Iomab-B
Jul 22, 2019
CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML
Jul 12, 2019
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
Jul 12, 2019
Janssen Submits Application to U.S. FDA Seeking Approval of New DARZALEX® (daratumumab) Subcutaneous Formulation
Jul 11, 2019
HealthTree® Patient Portal Surpasses 4,200 Users Representing 4% of All Multiple Myeloma Patients in the U.S.
Jul 10, 2019
Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation
Jul 03, 2019
FDA approves new treatment for refractory multiple myeloma
Jun 27, 2019
Letairis (ambrisentan; Gilead/GlaxoSmithKline) Market to 2025: A Selective Endothelin Type A Receptor Antagonist
Jun 26, 2019
Tracleer (bosentan; Johnson & Johnson) Drug Overview & Product Profiles 2016-2025
Jun 26, 2019
Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 24, 2019
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist
Jun 24, 2019
AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality
Jun 20, 2019
Actinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 19, 2019
World Multiple Myeloma Disease Coverage Forecast and Market 2018-2024: Leading Multiple Myeloma Drugs will Soon Face Generic Competition
Jun 17, 2019
Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings
Jun 16, 2019
New Data Presented from Oncopeptides' Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress
Jun 14, 2019
Tolero Pharmaceuticals Presents Clinical Data from Ongoing Phase 1 Zella 101 Study Evaluating Investigational Agent Alvocidib in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed AML at EHA 2019
Jun 14, 2019
New Data Presented at 24th EHA Congress From Oncopeptides' Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

Pages